#ASCO25 day 4: early LBA session in #BreastCancer A possible new SOC in the first-line setting for HER2+ MBC DESTINY-Breast09: - Median PFS was significantly improved with T-DXd+P vs THP (40.7 months vs 26.9 months) - Benefit consistent across subgroups - Median DOR > 3 years

Important to note that in the randomized trial showing equivalence of TCHP and THP that patients got 18 weeks of therapy with THP (not the more common 12 weeks) which might account for both higher pCR rates and lack of need for carboplatin.

👉Results of IMforte trial of: 👉Lurbinectedin + Atezolizumab as 1st line #Maintenance Tx in Extensive stage small cell lung cancer 👉significant improvement in pfs hr 0.54 👉significant improvement in os hr 0.73 #ASCO25 #ASCO #OncoDaily #larvol #oncology OncoAlert

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

#ASCO25 And another one! Journal of Clinical Oncology: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc Nina Shah)

NSABP B-51: RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1) 5y iBCRF➡️92.7% vs 91.8% 5y OS➡️93.6% vs 94.0% 💥No clear benefit from RNI in patients downstaged to ypN0 📌HR+/HER2– needs longer follow-up 📌TNBC may even fare worse with RNI nejm.org/doi/full/10.10…

These are important data and should change practice for LGL leukemia. Oncology Brothers

What patients are eligible for adjuvant CDK4/6i? We looked at this in ConcertAI: the approval of ribo doubled the pts eligible for adjuvant CDK4/6i (15%➡️30%) and provided an option for 10% of pts with N0 disease, those with the most aggressive cancers. esmoopen.com/article/S2059-…

📘3 recent updates in NCCN guidelines based on recent studies/approvals ✅Advanced anal SCC, 1L Retifenlimab-carbo-pacli ✅Unres/met pheochromocytoma/paraganglioma Belzutifan ✅Cancer assos VTE Apixaban reduced to 2x2.5 mg after 6months #cancer #oncology #MedX OncoAlert

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦UPMC Hillman Cancer Center⁩ ir.exelixis.com/news-releases/…

Please take a moment to read this blog on the recently activated NRG-GI011 trial in locally advanced #PancreaticCancer ! 👇

The NCCN has included adjuvant atezolizumab (for 1 year) in the treatment of stage pT2c–III dMMR colon cancer. Given the positive trial results, its inclusion is certainly appropriate. However, the guideline adopts a somewhat conservative stance regarding neoadjuvant ICI use,

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

Prospective study of stereotactic radiation for treatment of brain metastases (1-10) in SCLC (instead of whole brain radiation) Journal of Clinical Oncology. In 100 pts (median number of metastases was 2), only 22% of pts required salvage WBRT, mOS 10.2m. ascopubs.org/doi/10.1200/JC…

‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! OncoAlert

Implications of BRAF V600E in dMMR/MSI-H pts treated with ICIs. Prognostic impact of the BRAF V600E mutation in patients with MSI-high... sciencedirect.com/science/articl… AACR Journal of Clinical Oncology ASCO Mayo Clinic Comprehensive Cancer Center

I absolutely can’t wait to read this new memoir out from my friend Dr. Nasser Hanna Nasser Hanna , a #LungCancer med onc who has been an inspiration and role to me for 20 years. His wisdom is unparalleled. Check it out!! Congrats Nasser!!! ASCO Tatiana Prowell, MD Chris Draft

🆕🗞️Hot off the press! Nature Medicine #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽 More to come with the randomized study📚✔️! Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations. OncoAlert 🔗nature.com/articles/s4159…

KEYNOTE905: #Pembrolizumab + #EnfortumabVedotin before & after cystectomy improved EFS, OS & pCR vs surgery alone. A new SOC may be on the horizon for this high-risk group can’t wait to see the full data! #BladderCancer #Oncology #Immunotherapy #ADCake brando Andrea Necchi

EV303: EV-Pembro Significantly Improved Event-Free and Overall Survival and pCRs in cis-ineligible MIBC pts. A practice changing trial to be presented at #ESMO25 ⁦OncoAlert⁩ ⁦SEOM⁩ ⁦GUARD Consortium⁩ ⁦ESMO - Eur. Oncology⁩ merck.com/news/keytruda-…